COLUMBIA, Md.--(BUSINESS WIRE)--Celsion Corporation (NASDAQ: CLSN) announced today that it has completed a critical regulatory step in the countries of China and Japan to rapidly enroll patients in its global Phase III ThermoDox trial for the treatment of Hepatocellular Carcinoma (HCC), also known as primary liver cancer. The two instructional and educational meetings with principal investigators and institutional staffs were conducted in Tokyo and Beijing over the past ten days and were attended by over 60 physicians and surgeons who specialize in treating nonresectable liver cancer patients with radiofrequency ablation.
